IRAK inhibitor 4

• CAT Number: I000120
• CAS Number: 1012104-68-5
• Molecular Formula: C33H35F3N6O3
• Molecular Weight: 620.66
• Purity: ≥95%
• Synonyms: 1-(4-hydroxycyclohexyl)-N-(3-methylbutyl)-2-[[5-[2-(trifluoromethoxy)phenyl]-1H-indazol-3-yl]amino]benzimidazole-5-carboxamide
• Target: IRAK
• Solubility: DMSO: ＜ 10 mg/mL
• Storage: Store at -20°C
• InChI: 1S/C33H35F3N6O3/c1-19(2)15-16-37-31(44)21-8-14-28-27(18-21)38-32(42(28)22-9-11-23(43)12-10-22)39-30-25-17-20(7-13-26(25)40-41-30)24-5-3-4-6-29(24)45-33(34,35)36/h3-8,13-14,17-19,22-23,43H,9-12,15-16H2,1-2H3,(H,37,44)(H2,38,39,40,41)
• InChIKey: QZMAOGLWCNTFCG-UHFFFAOYSA-N
• SMILES: CC(C)CCNC(=O)C1=CC2=C(C=C1)N(C(=N2)NC3=NNC4=C3C=C(C=C4)C5=CC=CC=C5OC(F)(F)F)C6CCC(CC6)O

IRAK Inhibitor 4 (Cat No.: I000120) is a potent and selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with an IC₅₀ of 300 nM. It disrupts Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, making it a valuable tool for studying inflammation and immune responses. By blocking IRAK4 activity, it helps investigate therapeutic strategies for autoimmune diseases, inflammatory disorders, and certain cancers. IRAK Inhibitor 4 is widely used in immunology research to explore the regulation of innate immune signaling.

Reference

[1]. Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency. Clin Microbiol Rev. 2011 Jul;24(3):490-7. doi: 10.1128/CMR.00001-11.
[2]. Pourbasheer E, Riahi S, Ganjali MR, Norouzi P. Quantitative structure-activity relationship (QSAR) study of interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor activity by the genetic algorithm and multiple linear regression (GA-MLR) method. J Enzyme Inhib Med Chem. 2010 Dec;25(6):844-53.
[3]. Dunne A, Carpenter S, Brikos C, Gray P, Strelow A, Wesche H, Morrice N, O/’Neill LA. IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and degradation of MyD88 adaptor-like (Mal). J Biol Chem. 2010 Jun 11;285(24):18276-82.
[4]. Wang Z, Wesche H, Stevens T, Walker N, Yeh WC. IRAK-4 inhibitors for inflammation. Curr Top Med Chem. 2009;9(8):724-37.
[5]. Buckley GM, Fosbeary R, Fraser JL, Gowers L, Higueruelo AP, James LA, Jenkins K, Mack SR, Morgan T, Parry DM, Pitt WR, Rausch O, Richard MD, Sabin V. IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3656-60.